Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Pleased to share for your weekend reading my commentary in Nature Communications Nature Portfolio
‘Tissue-agnostic cancer therapies: promise, reality, and the path forward’
- Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. A study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications.
- Despite nine FDA approvals, real-world implementation challenges persist.
- Progress depends on universal genomic testing, an oncogenomic-savvy workforce, innovative trials, updated regulations, and real-world evidence to maximize potential.”
Title: Tissue-agnostic cancer therapies: promise, reality, and the path forward
Author: Vivek Subbiah
Read the Full Article on Nature Communications
More posts featuring Cancer Treatment.